Cardioxyl gets $15M and positive data on lead program

Cardioxyl Pharmaceuticals has rounded up $15 million and positive early-stage safety data, positioning the start-up developer for a mid-stage clinical trial of its lead therapy for cardiovascular disease. Aurora Funds and New Enterprise Associates provided the fresh infusion of cash. Researchers investigated CXL-1020 in 28 patients at seven sites, citing positive safety and tolerability results for the subjects suffering from chronic stable heart failure. The program is now bound for a Phase II...